The Role and Mechanism of Paeoniae Radix Alba in Tumor Therapy.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, c1995-

Paeonia* ; Medicine* ; Neoplasms*/drug therapy ; Drugs, Chinese Herbal* ; Plant Extracts*; Humans ; China

Tumors have a huge impact on human life and are now the main cause of disease-related deaths. The main means of treatment are surgery and radiotherapy, but they are more damaging to the organism and have a poor postoperative prognosis. Therefore, we urgently need safe and effective drugs to treat tumors. In recent years, Chinese herbal medicines have been widely used in tumor therapy as complementary and alternative therapies. Medicinal and edible herbs are popular and have become a hot topic of research, which not only have excellent pharmacological effects and activities, but also have almost no side effects. Therefore, as a typical medicine and food homology, some components of Paeoniae Radix Alba (PRA, called Baishao in China) have been shown to have good efficacy and safety against cancer. Numerous studies have also shown that Paeoniae Radix Alba and its active ingredients treat cancer through various pathways and are also one of the important components of many antitumor herbal compound formulas. In this paper, we reviewed the literature on the intervention of Paeoniae Radix Alba in tumors and its mechanism of action in recent years and found that there is a large amount of literature on its effect on total glucosides of paeony (TGP) and paeoniflorin (PF), as well as an in-depth discussion of the mechanism of action of Paeoniae Radix Alba and its main constituents, with a view to promote the clinical development and application of Paeoniae Radix Alba in the field of antitumor management.

World J Gastroenterol. 2015 Jun 21;21(23):7197-207. (PMID: 26109806)
J Exp Clin Cancer Res. 2011 Sep 26;30:87. (PMID: 21943236)
J Cell Physiol. 2021 Aug;236(8):5512-5532. (PMID: 33580511)
Nat Med. 2021 Jan;27(1):34-44. (PMID: 33442008)
Phytomedicine. 2010 Mar;17(3-4):254-60. (PMID: 19758795)
Front Vet Sci. 2022 Apr 04;9:839450. (PMID: 35445094)
J Ethnopharmacol. 2011 Apr 26;135(1):162-72. (PMID: 21396995)
J Ethnopharmacol. 2022 Oct 28;297:115550. (PMID: 35863612)
Cancer Res. 2019 Sep 15;79(18):4557-4566. (PMID: 31350295)
Exp Mol Med. 2022 Jan;54(1):1-11. (PMID: 35079119)
Biomolecules. 2021 Mar 16;11(3):. (PMID: 33809755)
Bratisl Lek Listy. 2014;115(7):427-33. (PMID: 25077366)
Front Pharmacol. 2021 Jan 22;11:594050. (PMID: 33716724)
Cell. 2023 Apr 13;186(8):1564-1579. (PMID: 37059065)
Int J Mol Sci. 2019 Jun 05;20(11):. (PMID: 31195692)
J Ethnopharmacol. 2020 Aug 10;258:112913. (PMID: 32371143)
Zhong Xi Yi Jie He Xue Bao. 2012 Apr;10(4):436-47. (PMID: 22500718)
Biosci Rep. 2019 Jan 18;39(1):. (PMID: 30530866)
Curr Pharm Biotechnol. 2021;22(9):1246-1253. (PMID: 33038910)
Cell Cycle. 2018;17(2):240-249. (PMID: 29301438)
Int Immunopharmacol. 2022 Oct;111:109122. (PMID: 35964411)
Drug Des Devel Ther. 2021 Jan 22;15:245-257. (PMID: 33519190)
Phytomedicine. 2021 Oct;91:153693. (PMID: 34403877)
Int J Biol Macromol. 2020 Dec 1;164:1554-1564. (PMID: 32735927)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Ann Med. 2022 Dec;54(1):413-425. (PMID: 35098831)
Biomed Pharmacother. 2020 Jan;121:109570. (PMID: 31710893)
Bioact Mater. 2020 Dec 26;6(7):1973-1987. (PMID: 33426371)
Anticancer Drugs. 2013 Feb;24(2):140-9. (PMID: 23069790)
Life Sci. 2011 Feb 14;88(7-8):350-7. (PMID: 21167840)
J Integr Med. 2014 Jul;12(4):331-5. (PMID: 25074882)
Cell Prolif. 2020 Oct;53(10):e12894. (PMID: 32881115)
Biomed Res Int. 2019 Feb 11;2019:9053295. (PMID: 30886866)
Adv Healthc Mater. 2023 Sep;12(23):e2300376. (PMID: 37161587)
Mol Cancer. 2019 Apr 2;18(1):75. (PMID: 30940145)
J Oncol. 2022 Sep 23;2022:5300523. (PMID: 36193202)
J Integr Med. 2017 Jan;15(1):1-7. (PMID: 28088253)
Biomed Pharmacother. 2019 Oct;118:109276. (PMID: 31377466)
Mol Med Rep. 2015 Aug;12(2):2735-40. (PMID: 25954855)
Nat Commun. 2020 Jan 24;11(1):486. (PMID: 31980632)
Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3855-3864. (PMID: 29949179)
J Pharm Pharmacol. 2020 Apr;72(4):483-495. (PMID: 31858611)
J Cell Biochem. 2018 Jul;119(7):5704-5714. (PMID: 29388711)
Phytother Res. 2011 Oct;25(10):1551-7. (PMID: 21698669)
Front Pharmacol. 2022 Feb 02;12:785790. (PMID: 35185538)
Soc Sci Med. 2022 Jan;292:114621. (PMID: 34883312)
Int J Mol Sci. 2020 Apr 09;21(7):. (PMID: 32283655)
Cancer Res. 2022 Apr 1;82(7):1267-1282. (PMID: 35135811)
Mol Med Rep. 2018 Apr;17(4):5095-5101. (PMID: 29363721)
J Anal Methods Chem. 2021 May 15;2021:8860776. (PMID: 34094615)
Biol Pharm Bull. 2015;38(7):1005-11. (PMID: 25972092)
Pharmacol Res. 2021 Aug;170:105728. (PMID: 34119622)
Nat Metab. 2022 May;4(5):534-546. (PMID: 35655026)
Sci Rep. 2018 Jul 18;8(1):10865. (PMID: 30022028)
Int J Mol Sci. 2022 Jan 25;23(3):. (PMID: 35163253)
J Clin Invest. 2018 Jul 2;128(7):2848-2861. (PMID: 29596064)
Phytomedicine. 2024 May;127:155483. (PMID: 38432036)
Eur J Clin Nutr. 2021 Feb;75(2):267-273. (PMID: 32884122)
J Sep Sci. 2021 Jun;44(12):2427-2437. (PMID: 33885223)
Int J Nanomedicine. 2020 Nov 17;15:9049-9059. (PMID: 33235451)
Int J Oncol. 2019 Feb;54(2):407-419. (PMID: 30570109)
Chem Biodivers. 2022 Aug;19(8):e202200295. (PMID: 35841592)
Drug Des Devel Ther. 2015 Oct 13;9:5611-22. (PMID: 26508835)
Sci Rep. 2016 Sep 09;6:32809. (PMID: 27609096)
Int J Mol Sci. 2022 Jan 21;23(3):. (PMID: 35163079)
Zhongguo Zhong Yao Za Zhi. 2019 Dec;44(24):5496-5502. (PMID: 32237400)
Antioxidants (Basel). 2021 Jul 02;10(7):. (PMID: 34356304)
J Toxicol Environ Health A. 2018;81(12):502-511. (PMID: 29630468)
J Pharm Biomed Anal. 2018 Oct 25;160:276-288. (PMID: 30144752)
Pharmacol Ther. 2021 May;221:107753. (PMID: 33259885)
Evid Based Complement Alternat Med. 2022 Nov 29;2022:2442681. (PMID: 36482932)
Adv Clin Chem. 2016;74:103-41. (PMID: 27117662)
Med Sci Monit. 2018 Sep 12;24:6405-6413. (PMID: 30208371)
Neurochem Res. 2018 Mar;43(3):760-774. (PMID: 29423667)
Int Immunopharmacol. 2021 Dec;101(Pt B):108364. (PMID: 34844873)
Arch Med Res. 2017 Oct;48(7):569-581. (PMID: 29452699)
Aging (Albany NY). 2021 Jul 28;13(14):18287-18297. (PMID: 34319254)
Semin Immunol. 2020 Apr;48:101409. (PMID: 32958359)
Inflamm Res. 2023 Jan;72(1):159-169. (PMID: 36357814)
J Immunol Res. 2021 Sep 14;2021:9659304. (PMID: 34557554)
Int J Mol Sci. 2020 Sep 04;21(18):. (PMID: 32899616)
Biomed Pharmacother. 2022 May;149:112800. (PMID: 35279012)
Food Funct. 2015 Aug;6(8):2803-12. (PMID: 26169959)
Biol Trace Elem Res. 2021 Jun;199(6):2375-2386. (PMID: 32808068)
Science. 2018 Aug 10;361(6402):607-612. (PMID: 30093599)
Clin Exp Pharmacol Physiol. 2008 Feb;35(2):141-7. (PMID: 17941899)
Inflammation. 2019 Dec;42(6):2215-2225. (PMID: 31473900)
Biomed Pharmacother. 2016 Mar;78:197-203. (PMID: 26898442)
Acta Pharm. 2018 Jun 1;68(2):211-222. (PMID: 29702481)
Food Chem Toxicol. 2012 May;50(5):1560-7. (PMID: 22326807)
Nat Commun. 2016 Apr 04;7:11151. (PMID: 27039827)
Chin J Integr Med. 2019 Nov;25(11):837-844. (PMID: 30361813)
Semin Cancer Biol. 2022 Jan;78:90-103. (PMID: 33979674)
Mol Cancer. 2023 Feb 1;22(1):23. (PMID: 36726126)
Int J Mol Sci. 2020 Dec 20;21(24):. (PMID: 33419373)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
J Oncol. 2021 Jan 19;2021:4724938. (PMID: 33531900)
Int J Mol Sci. 2021 Mar 26;22(7):. (PMID: 33810350)
Curr Res Food Sci. 2022 Oct 07;5:1882-1896. (PMID: 36276242)
Biosci Trends. 2021 Nov 21;15(5):283-298. (PMID: 34421064)
Cell Metab. 2019 Jul 2;30(1):36-50. (PMID: 31269428)
Acta Pharmacol Sin. 2016 Jun;37(6):794-804. (PMID: 27133302)
Front Pharmacol. 2019 Mar 19;10:231. (PMID: 30941036)
J Ethnopharmacol. 2013 Sep 16;149(2):443-52. (PMID: 23867078)
Chin Med J (Engl). 2021 Mar 17;134(7):783-791. (PMID: 33734139)
Drug Des Devel Ther. 2017 Aug 23;11:2481-2491. (PMID: 28860718)
Pharm Biol. 2019 Dec;57(1):543-549. (PMID: 31429615)
J Pharm Pharmacol. 2021 Jul 7;73(8):1039-1048. (PMID: 33749788)
Front Immunol. 2021 Jan 21;11:609705. (PMID: 33552068)
J Ethnopharmacol. 2021 Jan 10;264:113281. (PMID: 32810624)
J Clin Invest. 2021 Jan 4;131(1):. (PMID: 33108355)
Funct Plant Biol. 2019 Jan;46(2):107-117. (PMID: 32172753)
Mol Med Rep. 2016 Sep;14(3):2143-9. (PMID: 27430753)
Biomed Pharmacother. 2008 Nov;62(9):659-66. (PMID: 18809274)
Eur J Pharmacol. 2014 Oct 5;740:364-78. (PMID: 25058905)
Nutrients. 2018 Aug 04;10(8):. (PMID: 30081573)
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(3):356-363. (PMID: 32762162)
Cancer Med. 2019 May;8(5):1958-1975. (PMID: 30945475)
Nat Rev Drug Discov. 2019 Mar;18(3):175-196. (PMID: 30622344)
Arch Pharm Res. 2007 Oct;30(10):1179-85. (PMID: 18038896)

2023BEG02015 Ningxia Key Research and Development Program; 2022AAC02039 Ningxia Natural Science Foundation; 2022-226 High-level Key Discipline Construction Project of State Administration of Traditional Chinese Medicine

Keywords: Paeoniae Radix Alba; medicine and food homology; molecular mechanism; tumor therapy

3Z3866YW6P (peony root extract)
0 (Drugs, Chinese Herbal)
0 (Plant Extracts)

Date Created: 20240413 Date Completed: 20240415 Latest Revision: 20240425

20240425

PMC11012976

10.3390/molecules29071424

38611704